rme-2019-0145.pdf (664.38 kB)
Dimethyl sulfoxide: a central player since the dawn of cryobiology, is efficacy balanced by toxicity?
journal contribution
posted on 2020-05-12, 14:25 authored by Maooz Awan, Iryna Buriak, Roland Fleck, Barry Fuller, Anatoliy Goltsev, Julie Kerby, Mark Lowdell, Pavel Mericka, Alexander Petrenko, Yuri Petrenko, Olena Rogulska, Alexandra StolzingAlexandra Stolzing, Glyn N StaceyDimethyl sulfoxide (DMSO) is the cryoprotectant of choice for most animal cell systems since the early history of cryopreservation. It has been used for decades in many thousands of cell transplants. These treatments would not have taken place without suitable sources of DMSO that enabled stable and safe storage of bone marrow and blood cells until needed for transfusion. Nevertheless, its effects on cell biology and apparent toxicity in patients have been an ongoing topic of debate, driving the search for less cytotoxic cryoprotectants. This review seeks to place the toxicity of DMSO in context of its effectiveness. It will also consider means of reducing its toxic effects, the alternatives to its use and their readiness for active use in clinical settings.
History
School
- Mechanical, Electrical and Manufacturing Engineering
Published in
Regenerative MedicineVolume
15Issue
3Pages
1463 - 1491Publisher
Future MedicineVersion
- VoR (Version of Record)
Rights holder
© The AuthorsPublisher statement
This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/Acceptance date
2020-03-27Publication date
2020-04-28Copyright date
2020ISSN
1746-0751eISSN
1746-076XPublisher version
Language
- en
Depositor
Prof Alexandra Stolzing. Deposit date: 12 May 2020Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC